This document evaluates the economic impact of home enzyme therapy administration (HETA) compared to in-hospital therapy (iHp) and ambulatory hospitalization (AHp) for patients with Fabry disease and Gaucher disease in Spain. Direct and indirect expenses are estimated for the different treatment strategies. Results show that HETA provides significant cost savings to the health system and avoids lost work productivity costs compared to iHp and AHp. An electronic tool was created to calculate treatment costs for individual patients to help compare treatment strategies and their impact on health systems. The HETA program provides effective treatment with significant economic benefits added to improved patient satisfaction.